Esophageal cancer
Conditions
Interventions
Sponsors
Air Force Specialty Medical Center, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Malignant tumors of the thoracic esophagus confirmed by pathology as squamous cell carcinoma. 2. The clinical stage before treatment is locally advanced (T3-4aN0-1M0) or local early with regional lymph node metastasis (T1-2N1M0). 3. The expected survival time is greater than 6 months. 4. Aged 18-65 years, with a KPS score> 80 (see Annex 1 for the KPS scoring standard). 5. Laboratory test indicators must meet the following requirements: Blood routine: white blood cell >=4.0x10^9/L, neutrophil >=1.5x10^9/L, platelet count >=100x10^9/L, hemoglobin >=90g/L; Liver and kidney function: serum bilirubin is lower than 1.5 times the maximum normal value, ALT and AST are lower than 1.5 times the maximum normal value, BUN and Cr are within the normal range. 6. The patient has not received formal anti-tumor therapy in the past. 7. Able to understand the situation of this research and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are high risk factors for esophageal perforation. 2. Anti-tumor therapy (including chemotherapy, radiotherapy, and surgery) has been performed. 3. Those who are known or suspected to be allergic to chemotherapy drugs such as paclitaxel and lobaplatin. 4. Presence or coexistence of bleeding disorders. 5. Other uncontrollable and inoperable patients. 6. Patients during pregnancy and lactation. 7. Due to previous operations, the gastroesophagus can not be used to reconstruct the digestive tract in this operation. 8. Patients with peripheral neuropathy, CTC grade >= 2. 9. Patients with a history of malignant tumors other than esophageal cancer before enrollment, except for non-melanoma skin cancer and cervical cancer in situ. 10. The researcher thinks it is inappropriate to participate in this research. 11. Patients with severe heart, lung, liver, kidney insufficiency, hematopoietic system diseases, immune system diseases, cachexia and other intolerable surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival rate;1, 2 year survival rate;Objective remission rate;Toxic and side effects;Adverse Events; | — |
Countries
China
Contacts
Public ContactYan Maohui
Air Force Specialty Medical Center, PLA
Outcome results
None listed